Improving care of chronic heart failure: Advances from drugs to devices

Randall C. Starling, MD, MPH
Section of Heart Failure and Cardiac Transplant Medicine, Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Randall C. Starling, MD, MPH, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

The author has indicated that he has received grant or research support from Acorn Cardiovascular corporation, and is a consultant for Novartis.

This paper discusses therapies that are experimental or not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the authors but are not peer-reviewed.

Randall C. Starling, MD, MPH
Section of Heart Failure and Cardiac Transplant Medicine, Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Randall C. Starling, MD, MPH, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

The author has indicated that he has received grant or research support from Acorn Cardiovascular corporation, and is a consultant for Novartis.

This paper discusses therapies that are experimental or not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the authors but are not peer-reviewed.

Randall C. Starling, MD, MPH
Section of Heart Failure and Cardiac Transplant Medicine, Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Randall C. Starling, MD, MPH, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

The author has indicated that he has received grant or research support from Acorn Cardiovascular corporation, and is a consultant for Novartis.

This paper discusses therapies that are experimental or not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the authors but are not peer-reviewed.